NuCana plc (NCNA)
After hours:
| Previous close | 3.7900 |
| Open | 3.7000 |
| Bid | 3.6000 x 100 |
| Ask | 3.9800 x 100 |
| Day's range | 3.4000 - 3.8200 |
| 52-week range | 3.4000 - 23.7500 |
| Volume | |
| Avg. volume | 71,931 |
| Market cap | 7.982M |
| Beta (5Y monthly) | 0.94 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -16.4700 |
| Earnings date | 15 May 2024 - 20 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 125.07 |
- Globe Newswire
NuCana Announces Completion of ADS Ratio Change
EDINBURGH, United Kingdom, April 16, 2024 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced that the Company’s previously disclosed plans to change the ratio of its American Depositary Shares (“ADSs”) to its ordinary shares from one (1) ADS, representing one (1) ordinary share, to one (1) ADS representing twenty-five (25) ordinary shares (the "ADS Ratio") has been made effective. The ADS Ratio Change became effective on April 16, 2024 (the “Effective Date”). For the Company's ADS holders,
- GlobeNewswire
NuCana Presents Data at the AACR 2024 Annual Meeting Highlighting the Ability of NUC-7738 to Profoundly Alter Tumor Biology in a Paired Biopsy Clinical Study
NUC-7738 Reprograms Cancer Cell Lipid Metabolism to Make Tumors Less Aggressive and Promote Cancer Cell Death NUC-7738 Alters Ribosome Biogenesis and the Regulation of Genes Critical for Cancer Growth and Survival SAN DIEGO, April 09, 2024 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced two posters being presented today at the American Association of Cancer Research (AACR) Annual Meeting. Title: Exposing the Heterogeneity of the Lipidome in the TME of Cutaneous Melanoma Following Treatme
- GlobeNewswire
NuCana Announces Plan to Implement ADS Ratio Change
EDINBURGH, United Kingdom, March 27, 2024 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced plans to change the ratio of its American Depository Shares (“ADSs”) to its ordinary shares from one (1) ADS, representing one (1) ordinary share, to one (1) ADS representing twenty-five (25) ordinary shares (the "ADS Ratio"). The change in the ADS Ratio is expected to become effective on or about April 16, 2024 (the "Effective Date"). For the Company's ADS holders, the change in the ADS Ratio has t
